ICON, which builds homes using 3D printing, has closed on $56 million in Series C funding co-led by Norwest Venture Partners ...
A surprising new study suggests that COVID-19 may not have originated from bats or pangolins, but rather from a rare fusion ...
Tax advantages offered by PEA-PME and PEA are only available to French residents. *Shares of European companies with fewer than 5,000 employees and an annual revenue of less than €1.5 billion or total ...
Qure is planning soon to start enrolling patients in a second dose group as part of a clinical trial testing AMT-162 for SOD1 ...
OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated ...
Our biological sciences students explore the complexities of life and work to address global challenges in biology. Our faculty advance knowledge in a wide range of disciplines within the biological ...
Department of Engineering Physics, McMaster University, 1280 Main Street West, L8S 4L8 Hamilton, Ontario, Canada School of Biomedical Engineering, McMaster University, 1280 Main Street West, L8S 4L8 ...
They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...
A requisite majority of H-class shareholders did not approve the buyout, the companies said. "The proposed privatisation of the Company (Henlius) will not proceed and the listing of the H Shares ...
Primarily, Ascentage hopes to leverage the IPO proceeds to advance its pipeline. Around $50 million to $60 million, for instance, will help the biotech pursue approval for its BCL-2 blocker ...
Erica Denhoff / Icon Sportswire via Getty Images Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu. The biotech ...
In 2019, Stanford University professor Irv Weissman and a colleague published a paper that represented a new way to target some aggressive cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback